Liquid Biopsy in Pituitary Neuroendocrine Tumors—Potential Biomarkers for Diagnosis, Prognosis, and Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094058 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ligia Gabriela Tataranu. Beteiligte Einrichtung: Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Biomarkers, Tumor, Neuroendocrine Tumors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy Carol Davila, Bucharest.
Abstract (Originalsprache)
Pituitary neuroendocrine tumors (PitNETs) are slow-growing neoplasms with various clinical presentations, often leading to diagnostic challenges. While neuroimaging assessment and histopathological evaluation remain the gold standard for diagnosis, emerging research highlights the potential of liquid biopsy, mainly through the analysis of circulating non-coding RNAs (ncRNAs), as a promising diagnostic and prognostic tool. Recent studies have demonstrated distinct expression profiles in different types and subtypes of tumors, with implications in assessing tumor aggressiveness and predicting treatment response. The current article summarizes data about potential biofluid markers implicated in PitNET development, mainly circulating tumor DNA (ctDNA), cell-free RNAs (cfRNA), circulating tumor cells (CTCs), and exosomes. Many studies on genetic and molecular markers in PitNET tissue samples provide exciting information about tumor biology, but to date, specific studies on liquid biopsy biomarkers are still few. Over the past years, a certain understanding of the mechanisms involved in pituitary tumorigenesis has been gained, including the landscape of genomic alterations, changes in epigenetic profile, crucial molecules involved in specific signaling pathways, and non-coding RNA molecules with critical roles in malignant transformation. Genetic and molecular characterization of the PitNETs could help distinguish between functional and non-functional PitNETs, different types and subtypes of pituitary tumors, and invasive and non-invasive forms. Further studies are required to identify and validate innovative biomarkers or therapeutic targets for treating PitNET. Integrating liquid biopsy into clinical workflows could revolutionize the management of pituitary adenomas, enabling more personalized and less invasive diagnostic and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
- Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania.
ORCID-Profile: Ligia Gabriela Tataranu
Förderung
- University of Medicine and Pharmacy Carol Davila, Bucharest
Zitieren
APA
Tataranu, L. G. (2025). Liquid Biopsy in Pituitary Neuroendocrine Tumors—Potential Biomarkers for Diagnosis, Prognosis, and Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094058
Vancouver
Tataranu LG. Liquid Biopsy in Pituitary Neuroendocrine Tumors—Potential Biomarkers for Diagnosis, Prognosis, and Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094058
BibTeX
@article{Tataranu2025,
author = {Tataranu, Ligia Gabriela},
title = {Liquid Biopsy in Pituitary Neuroendocrine Tumors—Potential Biomarkers for Diagnosis, Prognosis, and Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094058}
}
EUVIMED